Will you now recommend enfortumab and pembrolizumab for most patients with metastatic urothelial carcinoma, regardless of platinum eligibility, based on the EV 302 presentation at ESMO 2023?

The data presented at ESMO were paradigm-shifting. Within the constraints of insurance coverage, I will offer EVP to all patients with untreated metastatic urothelial cancer who are otherwise candidates for this therapy.